Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

MS07.03 Clinical Data

Journal of Thoracic Oncology

English

Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

Journal of Thoracic Oncology

English

P3.cr-11 ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report

Journal of Thoracic Oncology

English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

P1.05-15 Benign Lung Nodule Resections in the Era of Advanced Imaging and Clinical Guidelines: Imaging Features and How We Can Reduce the Resection Rate

Journal of Thoracic Oncology

English

P2.15-22 Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients With Diabetes Mellitus

Journal of Thoracic Oncology

English

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

Journal of Thoracic Oncology

English

P2.04-16 Correlation Between Programmed Death Ligand 1(pd-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients

Journal of Thoracic Oncology

English

P3.15-02 Carboplatin Dose Calculated Using Different Formula for eGFR and Their Comparison With Actual Dose Administered in Lung Cancer Patients

Journal of Thoracic Oncology

English

MA20.05 Who Gets Screened for Lung Cancer? A Simple Adjustment to Current Guidelines to Reduce Racial Disparities

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

MS07.03 Clinical Data

Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

P3.cr-11 ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

P1.05-15 Benign Lung Nodule Resections in the Era of Advanced Imaging and Clinical Guidelines: Imaging Features and How We Can Reduce the Resection Rate

P2.15-22 Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients With Diabetes Mellitus

P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review

P2.04-16 Correlation Between Programmed Death Ligand 1(pd-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients

P3.15-02 Carboplatin Dose Calculated Using Different Formula for eGFR and Their Comparison With Actual Dose Administered in Lung Cancer Patients

MA20.05 Who Gets Screened for Lung Cancer? A Simple Adjustment to Current Guidelines to Reduce Racial Disparities